Compounded Tirzepatide vs Zepbound 2026

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans on 3- and 6-month plans · cancel anytime

At a glance: compounded tirzepatide vs Zepbound

	Zepbound (brand)	Compounded tirzepatide
FDA-approved?	Yes	No
Active ingredient	Tirzepatide	Tirzepatide (base API)
Maker	Eli Lilly	State-licensed compounding pharmacy
List price / month	~$1,086	—
Self-pay / typical telehealth price	~$299–$449 (LillyDirect vials)	~$199–$399/mo via telehealth
Studied in clinical trials	Yes (SURMOUNT program)	No
Requires a prescription?	Yes	Yes
Dosing format	Standardized auto-injector pens / vials (2.5–15 mg)	Vials, dose set by prescriber
Insurance eligible?	Potentially (plan-dependent)	Generally not covered
What's typically included	Medication only	Varies; some programs include full clinical support
Boxed warning	Thyroid C-cell tumors (class warning)	Same class warning applies

Sources: Eli Lilly prescribing information; FDA drug compounding guidance; SURMOUNT clinical-trial data (brand-name Zepbound/Mounjaro only). Prices as of June 2026 and subject to change. Trial figures do not apply to compounded tirzepatide.

What is the difference between compounded tirzepatide and Zepbound?

The molecule is the same: tirzepatide, a dual GIP/GLP-1 receptor agonist. Everything else differs in ways that matter clinically and legally.

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Eli Lilly manufactures it under FDA-supervised processes — standardized formulation, validated potency, tamper-evident auto-injector pens and single-dose vials, and an ongoing post-market safety surveillance program. It went through extensive clinical trials before approval, including the SURMOUNT program.

Compounded tirzepatide is prepared patient-specifically by a state-licensed compounding pharmacy using tirzepatide as a raw active pharmaceutical ingredient (API). It is not FDA-approved: the FDA has not evaluated the compounded formulation's safety, efficacy, or quality. It was not studied in the SURMOUNT trials. There is no generic version of Zepbound — calling a compounded product "generic tirzepatide" is inaccurate and inconsistent with FDA guidance.

The distinction the FDA draws is important: compounding is intended for patients who have a specific clinical need that the approved product cannot meet — a particular dose, an allergy to an excipient, or a genuine access constraint. It is not intended as a routine lower-cost substitute for an FDA-approved product, though that is how it was widely used during the GLP-1 shortage era.

For a broader overview of how brand-name and compounded GLP-1s compare across both molecules, see our brand-name vs compounded GLP-1 overview.

How does the cost compare in 2026?

The cost gap between brand and compounded is real, though it has narrowed since the shortage era. Here is where prices stand as of June 2026 — re-verify figures before acting on them, as pricing changes frequently across all parties.

Zepbound (brand-name tirzepatide) pricing

• List price: approximately $1,086/month, per Lilly's published pricing at pricinginfo.lilly.com/zepbound.
• LillyDirect self-pay vials: Lilly now sells single-dose vials directly via its telehealth-affiliated pharmacy program at roughly $299–$449/month depending on dose (2.5 mg through 15 mg), bypassing traditional pharmacy markups. See LillyDirect for current pricing.
• With insurance: Copays vary widely. Many plans exclude GLP-1s for weight management or require prior authorization. If you have coverage, Zepbound is the only tirzepatide option eligible for it.

Compounded tirzepatide via telehealth pricing

• Market range: approximately $199–$399/month across telehealth platforms as of June 2026, reflecting variation in dose, included services, and plan length.
• Nouri's Program: compounded tirzepatide is included in an all-in-one program at $175/mo on the 6-month plan ($1,050 billed), $199/mo on the 3-month plan ($597 billed), or $225/mo billed monthly. The same price applies at any dose. The program includes the medication, a personalized nutrition plan, a movement plan, and access to U.S.-licensed clinicians.

Lilly's self-pay tier has narrowed the gap considerably against program-level compounded pricing. The right comparison is like-for-like: brand vials from LillyDirect are medication only, with a separate cost for the prescribing visit. A program that includes clinical support, nutrition, and fitness alongside the medication at a higher per-month cost may represent a different value proposition depending on what you need. For a current look at how telehealth GLP-1 pricing compares across providers, see the GLP-1 telehealth pricing dataset (2026) and our complete GLP-1 cost guide for 2026. For tirzepatide-specific pricing details, see tirzepatide cost breakdown and Zepbound cost without insurance.

What does each option include?

Sticker-price comparisons can mislead when the included services differ. The table below maps what you typically get with each path.

What you get	Zepbound (LillyDirect self-pay)	Nouri compounded tirzepatide program
Tirzepatide medication	Yes — FDA-approved vials	Yes — compounded vials (not FDA-approved)
Clinician consultation	Separate cost (your own provider or telehealth)	Included — U.S.-licensed physician review
Nutrition planning	No	Included — personalized plan
Fitness / movement plan	No	Included — personalized plan
Ongoing care support	No	Included — Nouri Care Team access
Dose flexibility	Fixed commercial dose steps (2.5–15 mg)	Prescriber-set; same price at any dose
Satisfaction guarantee	No	Nouri Promise: 30-day full refund on 3- and 6-month plans
Insurance eligible?	Yes (plan-dependent)	Generally no; may qualify for FSA/HSA reimbursement (confirm with plan administrator)

Compounded tirzepatide offered through Nouri is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound®. FSA/HSA reimbursement eligibility for compounded GLP-1 medications varies — confirm with your plan administrator.

What does the tirzepatide research actually show?

All published clinical data on tirzepatide's effectiveness is research on brand-name tirzepatide — Zepbound® or Mounjaro® — not on compounded versions. Compounded tirzepatide has not been studied in controlled trials. With that framing in place, here is what the published research shows for the branded drug:

• SURMOUNT-1 (Jastreboff et al., NEJM 2022): In a randomized controlled trial of brand-name tirzepatide in adults with obesity without type 2 diabetes, participants at the highest dose (15 mg) achieved an average body-weight reduction of approximately 20.9% over 72 weeks. Participants at lower doses averaged roughly 15–19.5% weight loss. These are population averages for the FDA-approved drug; individual results vary. Read the SURMOUNT-1 study →
• SURMOUNT-5 (head-to-head vs. semaglutide, NEJM 2025): A direct comparison trial found brand-name tirzepatide was associated with greater mean weight reduction than semaglutide 2.4 mg (Wegovy®) — approximately 20.2% vs. 13.7% — over 72 weeks. Both figures are results for the FDA-approved branded medications. Read the SURMOUNT-5 study →

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides a clinician- and patient-facing overview of how prescription weight-management medications work and what to discuss with a provider. For how tirzepatide and semaglutide compare on this trial data, see our tirzepatide vs. semaglutide comparison.

None of the trial figures above apply to compounded tirzepatide. Compounded versions of this drug have not been studied, are not FDA-approved, and outcomes may differ.

Is compounded tirzepatide legal in 2026?

Compounding tirzepatide from a state-licensed 503A pharmacy with a valid individual prescription remains legal — but the regulatory environment is meaningfully different from 2022–2024, when the shortage opened a broad pathway for compounders.

What changed when the shortage ended

Between roughly 2022 and late 2024, the FDA listed tirzepatide on its drug shortage list. That listing allowed 503A and some 503B facilities to compound it more freely. In late 2024, the FDA declared the tirzepatide shortage resolved, and the broad shortage-based allowance closed. Since then:

• 503A compounding pharmacies may still compound tirzepatide for individual patients with a valid prescription, when there is a genuine patient-specific need the commercial product cannot meet — a particular dose, an excipient allergy, or a documented access limitation.
• 503B outsourcing facilities (which historically could compound in bulk without patient-specific prescriptions) face proposed FDA restrictions on bulk-compounded tirzepatide. As of June 2026, the FDA's proposal had completed its public comment period; final guidance was pending.
• The FDA sent warning letters to compounders and telehealth platforms that marketed compounded GLP-1s using equivalence language or without adequate disclosures about the non-FDA-approved status of the compound.

What this means for patients

Compounded tirzepatide from a named, licensed 503A pharmacy with a legitimate, patient-specific prescription is a legal pathway in 2026. But the FDA's posture has shifted: the agency expects compounding to serve genuine clinical needs, not to be a wholesale substitute for an approved product. The pharmacy should be identifiable and its license verifiable.

Because compounded tirzepatide is not FDA-reviewed, the FDA notes that its safety, purity, and potency have not been formally evaluated by the agency. Risks from unverified sources — counterfeits, incorrect concentration, contamination — are a documented concern. Compounding from a named, licensed 503A pharmacy with a real prescription substantially reduces these risks but does not eliminate them. The FDA's guidance on human drug compounding and its postmarket safety information on compounded GLP-1 drugs are the authoritative sources for current rules.

Both Zepbound and compounded tirzepatide carry the class-level boxed warning for potential thyroid C-cell tumors. Both are contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and neither should be used during pregnancy.

How does access work for each option?

The practical path to each product differs in ways worth understanding before you decide.

Getting Zepbound

Zepbound requires a prescription from a licensed provider. You can obtain one through your own primary care physician or endocrinologist, a telehealth platform that prescribes it, or via Eli Lilly's own LillyDirect service (which connects you with affiliated providers and its own pharmacy). If insured, prior authorization is required by most plans. The LillyDirect self-pay vial program bypasses the insurance step but still requires a telehealth consult and prescription; auto-injector pens are also available through retail pharmacies at list price.

Getting compounded tirzepatide through Nouri

Nouri is an online telehealth program available in all 50 U.S. states. You complete a health questionnaire online; a U.S.-licensed physician on the Nouri Care Team reviews it and determines whether treatment is clinically appropriate. Not all applicants qualify — medication is prescribed only when indicated. If prescribed, your compounded tirzepatide is prepared by Jungle Jim's Pharmacy, a state-licensed 503A compounding pharmacy in Fairfield, OH, and ships free and discreetly to your home. The program also includes a personalized nutrition plan, a movement plan, and ongoing access to the Nouri Care Team — all at one price, at any dose.

For an overview of coverage options, see our guide on whether insurance covers Wegovy and Zepbound and using HSA/FSA funds for GLP-1s.

Related comparisons

• Compounded Semaglutide vs Wegovy — the parallel comparison for the semaglutide versions
• Brand-Name vs Compounded GLP-1: Full Overview
• Tirzepatide vs Semaglutide: Which Molecule Has Stronger Trial Data?
• Compounded vs Brand GLP-1: Cost Comparison

Where Nouri fits

If you and a licensed clinician determine a GLP-1 is appropriate for you, Nouri offers compounded tirzepatide as part of one complete program. The program includes the compounded medication when prescribed, a personalized nutrition plan, a movement plan, and ongoing access to U.S.-licensed clinicians — all at one price, at any dose.

Pricing: $175/mo on the 6-month plan ($1,050 billed); $199/mo on the 3-month plan ($597 billed); or $225/mo billed monthly.

Your medication is prepared by Jungle Jim's Pharmacy, a state-licensed 503A compounding pharmacy in Fairfield, OH, and ships free and discreetly in all 50 states. Nouri is LegitScript-certified.

Your enrollment is backed by the Nouri Promise: if you are not satisfied in your first 30 days, you receive a full refund — available on 3-month and 6-month plans.

Compounded tirzepatide contains the same active ingredient as Zepbound® (tirzepatide), but it is not FDA-approved, was not studied in Zepbound's trials, and is not the same as — or therapeutically equivalent to — Zepbound® or Mounjaro®. It is prescribed only when a licensed clinician determines it is clinically appropriate.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans on 3- and 6-month plans · cancel anytime

Frequently asked questions

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No. Compounded tirzepatide shares the same active ingredient (tirzepatide) but is not FDA-approved, was not studied in the SURMOUNT trials, and is not therapeutically equivalent to Zepbound® or Mounjaro®. There is no generic version of either brand-name drug.

Is compounded tirzepatide cheaper than Zepbound?

Often on sticker price: compounded tirzepatide via telehealth typically runs ~$199–$399/month, versus Lilly's ~$299–$449 self-pay vials (LillyDirect) or ~$1,086 list, as of June 2026. Prices change frequently. Compare like-for-like: brand vials are medication only, while some compounded programs include clinical support and lifestyle components at the quoted price.

Why is compounded tirzepatide less expensive than Zepbound?

Compounded tirzepatide is not manufactured, FDA-approved, or marketed as a brand-name drug — it is prepared patient-specifically by a licensed compounding pharmacy, without the research-and-development, clinical trial, and regulatory costs Eli Lilly incurred for Zepbound. The tradeoff: no FDA evaluation of the compounded product's safety, efficacy, or quality.

Is compounded tirzepatide legal in 2026?

Compounding from a state-licensed 503A pharmacy with a valid prescription remains legal. However, the FDA resolved the tirzepatide shortage in 2024–2025, ending the broad shortage-based compounding allowance. As of 2026, compounding is expected to be genuinely patient-specific and clinician-guided; further restrictions on bulk compounding at 503B facilities are also under consideration. Confirm current rules with a licensed clinician or pharmacy. Compounded tirzepatide is not FDA-approved.

Does insurance cover compounded tirzepatide?

Generally no — most commercial insurance plans do not cover compounded medications. Zepbound has potential for insurance coverage, though coverage for weight-management GLP-1s varies widely by plan and typically requires prior authorization. Compounded GLP-1 prescriptions may be eligible for FSA or HSA reimbursement under IRC §213(d) — typically with a receipt and, in some cases, a letter of medical necessity. Confirm eligibility with your plan administrator before assuming coverage.

Can I switch from Zepbound to compounded tirzepatide?

That is a clinical decision. A licensed provider should weigh your current dose, health history, insurance situation, and the reason for switching. Compounded and brand-name tirzepatide are not interchangeable products — any transition should be managed by a provider who can guide appropriate dosing and monitoring.

Sources & references

1. Jastreboff AM, et al. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022. (Tier 1 — primary trial of brand-name tirzepatide)
2. SURMOUNT-5: Tirzepatide vs Semaglutide head-to-head in obesity. NEJM 2025. (Tier 1 — primary head-to-head trial of brand-name tirzepatide)
3. Wilding JPH, et al. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021. (Tier 1 — primary trial of brand-name semaglutide)
4. FDA: Human Drug Compounding — regulatory guidance. (Tier 1)
5. FDA: Postmarket Drug Safety Information — Compounded GLP-1 Drugs. (Tier 1)
6. NIDDK: Prescription Medications to Treat Overweight and Obesity. (Tier 1 — NIH)
7. LillyDirect: Zepbound self-pay vial program (June 2026). (Tier 3 — manufacturer pricing)
8. Eli Lilly: Zepbound list price (June 2026). (Tier 3 — manufacturer pricing)
9. Nouri GLP-1 Telehealth Pricing Dataset 2026 — open pricing data across GLP-1 telehealth programs.

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · Last reviewed June 29, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

This article is general education, not medical advice — talk to a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from studies of the FDA-approved branded medications (Zepbound®, Mounjaro®); compounded tirzepatide has not been studied in these trials, is not FDA-approved, and is not the same as — or therapeutically equivalent to — the brand-name drugs. GLP-1 medications carry a boxed warning for thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2; other risks include pancreatitis and gallbladder disease, and GLP-1 medications are not for use in pregnancy. Prices are as of June 2026 and change frequently. FSA/HSA reimbursement eligibility for compounded medications varies — confirm with your plan administrator.